The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

CNBC's Brandon Gomez joins 'Squawk on the Street' to break down the controversy around Hims & Hers Super Bowl ads.

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Telehealth company Hims & Hers Health (HIMS) recently stirred up controversy with its ad promoting its compounded weight-loss ...

Telehealth company Hims & Hers is running its first Super Bowl ad and it appears to be poised to become one of the most talked about ads in recent memory. The 60 second spot is provocative and ...

Two new customer-led programs from Hims & Hers, the Hims & Hers Health Collective and the Hims & Hers Community Member Council, are born from the company's commitment to serving its customers in ...

Telehealth company Hims & Hers Health is fighting back after the drug industry’s main lobbying group called out its first Super Bowl ad as “misleading” and in potential violation of ...

Shares of Hims & Hers (HIMS) have jumped on Friday as the company is preparing to air its first Super Bowl ad promoting its compounded version of the GLP-1 weight loss drug semaglutide.

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 69.2 ...